OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $169.47 million. The enterprise value is $192.45 million.
| Market Cap | 169.47M |
| Enterprise Value | 192.45M |
Important Dates
The last earnings date was Tuesday, April 16, 2024, before market open.
| Earnings Date | Apr 16, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.18 million shares outstanding. The number of shares has decreased by -3.71% in one year.
| Shares Outstanding | 18.18M |
| Shares Change (YoY) | -3.71% |
| Shares Change (QoQ) | +6.85% |
| Owned by Insiders (%) | 12.17% |
| Owned by Institutions (%) | 72.44% |
| Float | 15.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 38.37 |
| PS Ratio | 2.37 |
| Forward PS | 1.80 |
| PB Ratio | 1.34 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.61 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3.04 |
| Quick Ratio | 2.80 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.31 |
Financial Efficiency
Return on equity (ROE) is -14.60% and return on invested capital (ROIC) is -16.16%.
| Return on Equity (ROE) | -14.60% |
| Return on Assets (ROA) | -12.50% |
| Return on Capital (ROIC) | -16.16% |
| Revenue Per Employee | $529,789 |
| Profits Per Employee | -$130,118 |
| Employee Count | 135 |
| Asset Turnover | 0.51 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.07% in the last 52 weeks. The beta is 1.01, so OptimizeRx's price volatility has been similar to the market average.
| Beta (1Y) | 1.01 |
| 52-Week Price Change | -37.07% |
| 50-Day Moving Average | 13.30 |
| 200-Day Moving Average | 11.53 |
| Relative Strength Index (RSI) | 21.01 |
| Average Volume (30 Days) | 115,140 |
Short Selling Information
The latest short interest is 655,979, so 3.61% of the outstanding shares have been sold short.
| Short Interest | 655,979 |
| Short Previous Month | 754,662 |
| Short % of Shares Out | 3.61% |
| Short % of Float | 4.35% |
| Short Ratio (days to cover) | 4.25 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $71.52 million and -$17.57 million in losses. Loss per share was -$1.03.
| Revenue | 71.52M |
| Gross Profit | 42.90M |
| Operating Income | -26.40M |
| Pretax Income | -25.16M |
| Net Income | -17.57M |
| EBITDA | -21.31M |
| EBIT | -23.71M |
| Loss Per Share | -$1.03 |
Balance Sheet
The company has $13.85 million in cash and $36.82 million in debt, giving a net cash position of -$22.97 million or -$1.26 per share.
| Cash & Cash Equivalents | 13.85M |
| Total Debt | 36.82M |
| Net Cash | -22.97M |
| Net Cash Per Share | -$1.26 |
| Equity / Book Value | 126.55M |
| Book Value Per Share | 6.96 |
| Working Capital | 36.45M |
Cash Flow
In the last 12 months, operating cash flow was -$7.24 million and capital expenditures -$861,422, giving a free cash flow of -$8.10 million.
| Operating Cash Flow | -7.24M |
| Capital Expenditures | -861,422 |
| Free Cash Flow | -8.10M |
| FCF Per Share | -$0.47 |
Margins
Gross margin is 59.98%, with operating and profit margins of -36.91% and -24.56%.
| Gross Margin | 59.98% |
| Operating Margin | -36.91% |
| Pretax Margin | -35.18% |
| Profit Margin | -24.56% |
| EBITDA Margin | -29.79% |
| EBIT Margin | -33.15% |
| FCF Margin | -11.33% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.71% |
| Shareholder Yield | 3.71% |
| Earnings Yield | -10.36% |
| FCF Yield | -4.78% |
Analyst Forecast
The average price target for OptimizeRx is $15.86, which is 70.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.86 |
| Price Target Difference | 70.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 1.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 3 |